WO2008004100A9 - Therapeutic compounds - Google Patents

Therapeutic compounds Download PDF

Info

Publication number
WO2008004100A9
WO2008004100A9 PCT/IB2007/001887 IB2007001887W WO2008004100A9 WO 2008004100 A9 WO2008004100 A9 WO 2008004100A9 IB 2007001887 W IB2007001887 W IB 2007001887W WO 2008004100 A9 WO2008004100 A9 WO 2008004100A9
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic compounds
methods
solvates
formula
preparation
Prior art date
Application number
PCT/IB2007/001887
Other languages
French (fr)
Other versions
WO2008004100A2 (en
WO2008004100A3 (en
Inventor
Simon Paul Planken
Scott Channing Sutton
Tin Hung Tran
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of WO2008004100A2 publication Critical patent/WO2008004100A2/en
Publication of WO2008004100A3 publication Critical patent/WO2008004100A3/en
Publication of WO2008004100A9 publication Critical patent/WO2008004100A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention provides compounds of formula (I), or pharmaceutically acceptable salts or solvates thereof, methods for their preparation, methods for their use, and pharmaceutical formulations comprising them.
PCT/IB2007/001887 2006-07-05 2007-06-25 Therapeutic compounds WO2008004100A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US70659706P 2006-07-05 2006-07-05
US60/706,597 2006-07-05
US91519907P 2007-05-01 2007-05-01
US60/915,199 2007-05-01

Publications (3)

Publication Number Publication Date
WO2008004100A2 WO2008004100A2 (en) 2008-01-10
WO2008004100A3 WO2008004100A3 (en) 2011-06-16
WO2008004100A9 true WO2008004100A9 (en) 2012-04-19

Family

ID=38894942

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/001887 WO2008004100A2 (en) 2006-07-05 2007-06-25 Therapeutic compounds

Country Status (1)

Country Link
WO (1) WO2008004100A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2257536A4 (en) 2008-02-14 2011-03-23 Amira Pharmaceuticals Inc Cyclic diaryl ether as antagonists of prostaglandin d2 receptors
JP2011518130A (en) 2008-04-02 2011-06-23 アミラ ファーマシューティカルズ，インク． Aminoalkylphenyl antagonist of prostaglandin D2 receptor
MX2010010877A (en) * 2008-04-04 2010-10-26 Irm Llc Compounds and compositions as itpkb inhibitors.
WO2010057118A2 (en) 2008-11-17 2010-05-20 Amira Pharmaceuticals, Inc. Heterocyclic antagonists of prostaglandin d2 receptors
CN102971314B (en) 2010-04-28 2016-03-23 拜耳知识产权有限责任公司 Ketone group heteroaryl piperidine and ketone group heteroaryl bridged piperazine derivatives are as sterilant
JP6986955B2 (en) * 2016-12-28 2021-12-22 キッセイ薬品工業株式会社 Method for producing pyrazole derivative

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1133385B (en) * 1960-04-14 1962-07-19 Zyma Blaes A G Chem Fab Process for the preparation of 3-pyrazyl-pyrazole derivatives
JP2003171381A (en) 2001-09-25 2003-06-20 Takeda Chem Ind Ltd Entry inhibitory agent
JP2003119137A (en) 2001-10-10 2003-04-23 Japan Tobacco Inc Hiv inhibitor
ES2281565T3 (en) 2001-10-26 2007-10-01 Istituto Di Richerche Di Biologia Molecolare P. Angeletti S.P.A. INHIBITORS OF THE INTEGRESS OF HIV OF TYPE DIHYDROXYPYRIMIDINE CARBOXAMIDE.
AU2002349675A1 (en) 2001-12-05 2003-06-17 Shionogi And Co., Ltd. Derivative having hiv integrase inhibitory activity
AU2002366604A1 (en) 2001-12-12 2003-06-23 Bristol-Myers Squibb Company Hiv integrase inhibitors
PL216539B1 (en) 2001-12-21 2014-04-30 Tibotec Pharm Ltd Broadspectrum heterocyclic substituted phenyl containing sulfonamide hiv protease inhibitors
ATE370948T1 (en) 2002-01-17 2007-09-15 Merck & Co Inc HYDROXYNAPHTHYRIDINONCARBONIC ACID AMIDES, WHICH ARE SUITABLE AS INHIBITORS OF HIV INTEGRASE
TW200306192A (en) 2002-01-18 2003-11-16 Bristol Myers Squibb Co Tricyclic 2-pyrimidone compounds useful as HIV reverse transcriptase inhibitors
US7645771B2 (en) 2002-12-13 2010-01-12 Smithkline Beecham Corp. CCR5 antagonists as therapeutic agents
US20080188527A1 (en) * 2003-12-23 2008-08-07 Cashman John R Synthetic Compounds and Derivatives as Modulators of Smoking or Nicotine Ingestion and Lung Cancer
US7354938B2 (en) * 2004-03-23 2008-04-08 Amgen Inc. Pyrazole compounds and uses related thereto
US7662844B2 (en) * 2004-07-12 2010-02-16 Osi Pharmaceuticals, Inc. Naphthylene derivatives as cytochrome P450 inhibitors

Also Published As

Publication number Publication date
WO2008004100A2 (en) 2008-01-10
WO2008004100A3 (en) 2011-06-16

Similar Documents

Publication Publication Date Title
WO2007087548A3 (en) Chemical compounds
IL260127B (en) Mek inhibitors and methods of their use
WO2007027527A3 (en) Isoindole-imide compounds and compositions comprising and methods of using the same
WO2007034312A3 (en) Pyridinaminosulfonyl substituted benzamides as inhibitors of cytochrome p450 3a4 (cyp3a4)
MX2009000482A (en) Pyrazole derivatives as cytochrome p450 inhibitors.
MX2009003038A (en) 5-substituted quinazolinone derivatives and compositions comprising and methods of using the same.
WO2007135527A3 (en) Benzimidazolyl compounds
WO2006096444A3 (en) Chemical compounds
WO2008115516A8 (en) 4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same
WO2006011050A3 (en) Pyridine derivatives
WO2008027542A3 (en) 5-substituted isoindoline compounds
TW200613243A (en) Novel compounds
WO2006025070A3 (en) Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol
WO2009024611A3 (en) 4-benzylaminoquinolines, pharmaceutical compositions containing them and their use
WO2006082523A3 (en) Pharmaceutical sustained release composition of metformin
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
TW200626553A (en) Novel compounds
TW200639156A (en) New compounds
WO2007095039A3 (en) Pharmaceutical formulations
WO2009140341A3 (en) Atorvastatin compositions
WO2008008660A3 (en) Cyclopentane derivatives as antiglaucoma agents
WO2004105773A3 (en) Use of s1p
WO2008004100A9 (en) Therapeutic compounds
WO2008039894A3 (en) Atorvastatin pharmaceutical compositions
WO2005070903A3 (en) Sulphonamide substituted triazines as chemokine receptor modulators

Legal Events

Date Code Title Description
NENP Non-entry into the national phase in:

Ref country code: DE

NENP Non-entry into the national phase in:

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07734957

Country of ref document: EP

Kind code of ref document: A2